10-QPeriod: Q3 FY2023

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2023

Filed October 25, 2023For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported its third quarter and year-to-date results for the period ending September 30, 2023. Overall revenue for the quarter decreased by 7.7% to $2.3 billion, and for the nine-month period, it declined by 7.8% to $7.0 billion, primarily due to a significant reduction in COVID-19 testing revenues. The core "base business" excluding COVID-19 testing showed resilience, with revenue and volume increasing year-over-year for both periods. Despite revenue headwinds, the company managed its costs effectively, with operating income decreasing at a slower pace than revenues. Diluted earnings per share for the third quarter were $1.96, down from $2.17 in the prior year. Net income attributable to Quest Diagnostics for the quarter was $225 million, a decrease from $256 million in the same period last year. The company continued to make strategic investments, including significant acquisitions, and maintained its commitment to returning capital to shareholders through dividends and share repurchases, although no shares were repurchased in the nine months ended September 30, 2023, compared to substantial repurchases in the prior year.

Financial Highlights

57 data points
Beta

Revenue

$2.29B

32.9% Gross Margin

Net Income

$225.00M

9.8% Net Margin

EPS (Diluted)

$1.96

Total Assets

$13.48B

Cash & Equivalents

$143.00M

Free Cash Flow

$102.00M

Financial Statements
Beta
Revenue$2.29B
Cost of Revenue$1.54B
Gross Profit$754.00M
SG&A Expenses$380.00M
Operating Expenses$1.95B
Operating Income$342.00M
Interest Expense$41.00M
Net Income$225.00M
EPS (Basic)$1.99
EPS (Diluted)$1.96
Shares Outstanding (Basic)112.00M
Shares Outstanding (Diluted)114.00M

Key Highlights

  • 1Total net revenues for Q3 2023 decreased by 7.7% to $2.3 billion compared to Q3 2022, primarily driven by a decline in COVID-19 testing revenue.
  • 2The "base business" revenue (excluding COVID-19 testing) showed positive growth, increasing by 4.8% for the quarter and 8.2% for the nine-month period, indicating underlying operational strength.
  • 3Diluted Earnings Per Share (EPS) for Q3 2023 was $1.96, a decrease from $2.17 in Q3 2022, reflecting lower revenues and certain operating expenses.
  • 4The company completed significant acquisitions, including the laboratory services business of New York-Presbyterian ($275 million) and Haystack Oncology, Inc. ($392 million), to bolster its Diagnostic Information Services (DIS) segment.
  • 5Operating costs and expenses decreased by 6.7% in Q3 2023, with notable reductions in Cost of Services and Selling, General & Administrative (SG&A) expenses, helping to mitigate the impact of lower revenues.
  • 6Net cash provided by operating activities for the nine months ended September 30, 2023, was $745 million, a decrease from $1,384 million in the prior year, largely due to lower operating income and changes in COVID-19 testing revenue collection.
  • 7As of September 30, 2023, $1.3 billion remained available under the company's share repurchase authorization, though no shares were repurchased in the first nine months of 2023, a contrast to $950 million repurchased in the same period of 2022.

Frequently Asked Questions

The primary driver of the revenue decline in the third quarter of 2023 is the significant decrease in COVID-19 testing revenues. While this had a substantial impact on overall top-line results, the company's core 'base business' excluding COVID-19 testing demonstrated positive growth, indicating underlying demand for its services.

Quest Diagnostics is actively managing its costs through various initiatives. For the third quarter of 2023, cost of services decreased by 4.8% and Selling, General & Administrative (SG&A) expenses decreased by 18.1% year-over-year. This cost control, including reductions in performance-based compensation and headcount, helped to mitigate the impact of lower revenues on operating income.

The recent acquisitions, particularly of New York-Presbyterian's laboratory services and Haystack Oncology, are strategic investments aimed at expanding the company's Diagnostic Information Services (DIS) business. These acquisitions contributed to goodwill and intangible assets on the balance sheet. While they represent significant cash outflows ($699 million for the nine months ended September 30, 2023), they are intended to drive future revenue growth and market position in specialized areas like oncology testing.

For the nine months ended September 30, 2023, net cash provided by operating activities was $745 million. The company ended the period with $143 million in cash and cash equivalents. Management believes that current cash, cash flow from operations, and available credit facilities provide sufficient financial flexibility for ongoing operations, capital expenditures, debt service, dividends, and share repurchases, as well as future growth opportunities.